Why is CSPC Pharmaceutical stock surging today?
On Wednesday, CSPC Pharmaceutical's stock skyrocketed by 5.8% to HK$10.02 after the company announced that its Herpes Zoster vaccine, SYS 6052, had been approved for testing in the United States. This approval marks a significant milestone for the company, as it is the first recombinant protein vaccine from CSPC to clear the regulatory hurdle, having already received China's nod in July 2026.
Additionally, CSPC initiated a Phase Ib clinical trial for JMT206, a fully human monoclonal antibody aimed at weight management in overweight or obese adults. The positive news propelled CSPC ahead of a 0.2% decline in the Hang Seng index.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
